1 2

Primary Care Program Providing Inpatient Consultations for Children with Medical Complexity: a Pilot Randomized Quality Improvement Trial

3

BACKGROUND AND RATIONALE

Comprehensive care (**CC**) provided in the High-Risk Children's Clinic (**HRCC**) at The 4 5 University of Texas at Houston (UTH) McGovern Medical School involves care for acute and chronic conditions from a team of ethnically diverse pediatricians and nurse practitioners who 6 7 are knowledgeable about each patient and highly trained and experienced in treating medically complex and fragile children. This clinic serves as a novel medical home where both primary 8 and specialty services are provided in the same place at the same visit. Acute problems 9 presenting before 4 pm are seen the same day or if they occur over the weekend, on Monday 10 morning. All parents have the cell phone number to directly reach one of the primary care 11 12 clinicians at all hours. Multiple measures are used to promote and ensure the highest quality of 13 care such as daily checks of emergency department and hospital logs to ensure prompt followup and coordination of care, weekly HRCC provider team meetings to review the care provided 14 before every ED visit and hospitalization, high priority given to minimizing unnecessary ED visits 15 and hospitalizations, and a relatively low patient-to-staff ratio of no greater than 100 (to allow 16 17 for longer clinic visits, more telephone calls and e-mails, and extensive quality improvement measures). 18

19 Comprehensive care undoubtedly increases access to high-quality healthcare for high-20 risk disadvantaged chronically ill children. The findings of our previous randomized trial of comprehensive care vs. usual care that were given accelerated publication in JAMA (2014) have 21 attracted national attention as the best evidence to date supporting medical homes to reduce 22 either adverse outcomes or costs.¹ Comprehensive care resulted in major benefits (ED visits, 23 admissions, hospital days, and pediatric ICU admissions and days were all reduced by 47-69%) 24 and savings from the health system perspective were >\$10,000/child-year.¹ Indeed, the 25 26 improvements in outcomes and reduction in costs exceed those previously reported in prior studies of medical homes for patients of any age or condition. ¹⁻³ Despite these demonstrated 27 benefits, high-risk patients seen in the High-Risk Children's Clinic still experience high rates of 28

29 morbidity and often require hospitalization for treatment of acute exacerbations of their underlying chronic conditions. In 2015, a total of 100 HRCC patients experienced 175 30 admissions at Children's Memorial Hermann Hospital (CMHH) - that serves as the UTH tertiary 31 teaching hospital - for a mean length of stay of 7.1 days. As a result, a pilot quality 32 improvement (QI) trial will be conducted to assess the impact of offering inpatient consultation 33 (IC) by the HRCC providers at CMHH to further optimize coordination and integration of 34 35 inpatient and outpatient care and reduce total hospital days per child-year for the HRCC patients. 36

37

38 Hypotheses:

39 <u>Primary Hypothesis</u>: We hypothesize that relative to usual inpatient care, the inpatient

40 consultation service will decrease the total number of hospital days per child-year.

<u>Secondary Hypotheses</u>: We hypothesize that relative to usual inpatient care, the inpatient
 consultation service will:

Be cost-effective by either decreasing the number of hospital days per child-year without
 increasing health system costs, decreasing health system costs without increasing hospital
 days, or decreasing both.

46 2. Decrease the total number of PICU days per child-year at CMHH.

47 3. Decrease the 30-day ER visit rate following CMHH discharge.

48 4. Decrease the 30-day re-admission rate following CMHH discharge.

49 5. Increase parent/caregiver satisfaction as measured by pre-selected Hospital CAHPS survey

50 questions, which will be administered to the parent/caregiver 5-10 days after discharge

51 from the CMHH by study personnel who are not involved with the clinical care of patients.⁴

52 6. Increase the rate of inpatient consultations with the CMHH inpatient physician team during

admission - i.e. face-to-face consultations, non-face-to-face consultations, or a phone call

54 to the inpatient physician team.

55	7.	Increase the rate of follow-up phone calls from HRCC providers to parents/caregivers
56		within 36 hours after discharge from CMHH.
57	8.	Increasing the rate of follow-up clinic visits in the High-Risk Children's Clinic within 5-10
58		days after discharge from CMHH.
59	9.	Decrease the rate of serious illnesses (death, hospitalization > 7 days, or PICU admission)
60		during the study period.
61		
61 62		METHODS
61 62 63	Set	METHODS ting. The High-Risk Children's Clinic of the UTH is a patient-centered medical home for CMC.
61 62 63 64	Set Chi	METHODS ting. The High-Risk Children's Clinic of the UTH is a patient-centered medical home for CMC. Idren who require hospital care in our center are usually treated at Children's Memorial
61 62 63 64 65	Set Chi Her	METHODS ting. The High-Risk Children's Clinic of the UTH is a patient-centered medical home for CMC. Idren who require hospital care in our center are usually treated at Children's Memorial mann Hospital (CMHH), a private institution adjacent to our medical school that serves as
61 62 63 64 65 66	Set Chi Her the	METHODS ting. The High-Risk Children's Clinic of the UTH is a patient-centered medical home for CMC. Idren who require hospital care in our center are usually treated at Children's Memorial mann Hospital (CMHH), a private institution adjacent to our medical school that serves as UTH tertiary teaching hospital.

Inclusion/Exclusion criteria. HRCC patients who require admission to CMHH will be included in
the pilot trial. HRCC patients ≥ 18 years of age at study initiation will be excluded from the pilot
trial and so will those with a Do-Not-Resuscitate (DNR) order, unrepaired congenital heart
disease, active cancer, mitochondrial disorder, or seen in the HRCC clinic solely for
compassionate care.

Design. All eligible HRCC patients will be randomized to either comprehensive care with usual
 inpatient care or comprehensive care augmented with inpatient consultation utilizing a
 computer-generated algorithm with variable block sizes. Patients will be stratified by assigned
 provider and baseline clinical risk (high risk if < expected median risk or very high risk if >
 expected median risk, as judged by the clinic's medical director [R. Mosquera] based on
 diagnoses and prior clinical course).

78

79 Treatment Groups.

80 **Comprehensive Care with Usual Inpatient Care**. Includes comprehensive outpatient care in the

81 HRCC and usual inpatient care provided by the CMHH hospital inpatient team (residents,

82 fellows, and attending faculty physicians) with usual occasional communication with HRCC

83 providers. This care will not be modified by the study protocol.

<u>Comprehensive care Augmented with Inpatient Consultation</u>. Includes comprehensive
 outpatient care in the HRCC and inpatient consultation by HRCC providers during admissions at
 CMHH. The HRCC providers will review the inpatient care plan and make treatment and
 discharge recommendations to the hospital inpatient team with a focus on coordination and
 integration of inpatient and outpatient care. The inpatient consultations will consist of either
 face-to-face consultations, non-face-to-face consultations, or a phone call to the inpatient
 physicians at a minimum on admission and at discharge, including during observation stays.

Enrollment period. Enrollment will occur between October 3, 2016 and October 2, 2019 and
outcome evaluations will continue through either October 2, 2017 or 30 days after discharge
from last admission by October 2, 2017 (whichever comes later).

Data Collection and Management. Research Electronic Data Capture (REDCap) software will be utilized to collect and manage predefined study variable data. REDCap is a secure, web-based application designed to support electronic data capture for research studies providing: 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources.

100 **Cost Assessment.** The incremental costs of comprehensive care with inpatient consultation vs. 101 comprehensive care with usual inpatient care will be assessed from the health system perspective. Hospital costs for inpatient services will be obtained from the Memorial Hermann 102 Hospital institutional accounting system. Costs for professional services provided during CMHH 103 104 hospitalizations will be assessed based on Relative Value Units (RVUs) using UT Health claims data. The costs for hospitalizations occurring outside our center will be imputed based on the 105 106 mean costs for a hospital day at CMHH observed in our sample. Clinic costs for comprehensive care will be estimated using the total expenditures of the High-Risk Children's Clinic. Costs for 107

108 outpatient services provided in our center but outside the HRCC (such as diagnostic imaging 109 tests) will be calculated using the standard RVU-based method. The costs for the 110 comprehensive care with inpatient consultation group will be augmented by the HRCC 111 personnel time cost for providing inpatient consultation based on the HRCC staff salary and fringe data. All costs will be inflated to the year of analysis based on the Consumer Price Index 112 for medical services.⁵ The investigators will consider the program to be highly cost-effective if it 113 reduces the total number of hospital days per child-year without increasing costs, reduces costs 114 without increasing the total number of hospital days per child-year, or reduces both. 115

116 Statistical and Economic Analyses. All intent-to-treat statistical and economic analyses will be 117 performed using multilevel generalized estimating equations (GEE) models with exchangeable correlation to account for family clustering, robust standard errors, and log link. The economic 118 analyses will be performed according to current standards for such analyses.⁶⁻⁹ Differences in 119 120 hospital days and costs between treatment groups will be assessed using GEE models with gamma distribution. Rates of secondary outcomes will be assessed using binomial GEE models, 121 122 whereas total number of secondary outcomes will be assessed with negative binomial GEE models. All the models will be adjusted for the trial's stratifying variables (assigned provider 123 124 and baseline clinical risk) and for within-family correlation. In this small pilot study, some treatment effects that would be considered important by family members and clinicians 125 (reduced hospital days) may not be statistically significant. As a result, Bayesian analyses will 126 127 be performed to estimate the probability of a benefit of a given magnitude and evaluate 128 whether further study is justified. Neutral and skeptical priors will be used. The study will also 129 allow us to obtain the experience and data needed to refine the process for providing inpatient 130 consultations for high-risk chronically ill children. All frequentist statistical analyses will be performed using Stata version 13.1 (Stata Corp, College Station, TX). The Bayesian model will 131 be implemented using OpenBUGS. 132

Stopping Rules. We plan to enroll patients in the pilot trial for 3 years. However, under predefined stopping rules, enrollment will cease if Bayesian analyses performed at the end of the first year identifies a 80% or greater probability that inpatient consultation reduces the total number of hospital days per child-year relative to usual inpatient care. This analysis will

- use a neutral prior centered at RR of 1.0 with 95% prior interval of 0.3-3.3.
- 138 Ethics and Trial Registration. The Committee for the Protection of Human Subjects (CPHS) at
- 139 The University of Texas Health Science Center at Houston (UTHealth) determined that this
- 140 Quality Improvement (QI) Project does not require Institutional Review Board (IRB) approval.
- 141 This study is registered at ClinicalTrials.org (ID: NCT02870387).
- 142
- 143

144		References
145		
146	1.	Homer CJ, Klatka K, Romm D, et al. A review of the evidence for the medical home for
147		children with special health care needs. <i>Pediatrics</i> . Oct 2008;122(4):e922-937.
148	2.	Mosquera RA, Avritscher EB, Samuels CL, et al. Effect of an enhanced medical home on
149		serious illness and cost of care among high-risk children with chronic illness: a randomized
150		clinical trial. JAMA. Dec 24-31 2014;312(24):2640-2648.
151	3.	Jackson GL, Powers BJ, Chatterjee R, et al. The Patient-Centered Medical Home: A
152		Systematic Review. Annals of Internal Medicine. 2013;158(3):169-178.
153	4.	US Department of Health and Human Services; Agency for Healthcare Research and Quality.
154		CAPHS: surveys and tools to advance patient-centered care. <u>http://www.CAHPS.AHRQ.gov</u> .
155		Accessed July 29, 2016.
156	5.	U.S. Department of Labor. Bureau of Labor Statistics. Consumer Price Indexes. Accessible
157		at http://www.bls.gov/cpi/home.htm
158	6.	Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of
159		Health Care Programmes. 3rd ed. New York, NY: Oxford University Press; 2005.
160	7.	Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and
161		Medicine. New York, NY: Oxford University Press;1996.
162	8.	Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-
163		effectiveness analyses. Panel on Cost-Effectiveness in Health and
164		Medicine. JAMA 1996; 276: 1339–1341.
165	9.	Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO,
166		Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats
167		TG. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-
168		effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA.
169		2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195. PubMed ID: 27623463
170		
171		